While preclinical studies highlight the potential of annexin II inhibition and antioxidant therapies, their clinical application demands rigorous validation in APL-specific models and collaborative frameworks to address translational barriers. This evidence concerns the gene ANXA2 and acute promyelocytic leukemia.